<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37217189</PMID><DateCompleted><Year>2023</Year><Month>05</Month><Day>24</Day></DateCompleted><DateRevised><Year>2023</Year><Month>05</Month><Day>26</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2164-554X</ISSN><JournalIssue CitedMedium="Internet"><Volume>19</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Dec</Month><Day>31</Day></PubDate></JournalIssue><Title>Human vaccines &amp; immunotherapeutics</Title><ISOAbbreviation>Hum Vaccin Immunother</ISOAbbreviation></Journal><ArticleTitle>Preclinical safety evaluation of a bivalent inactivated EV71-CA16 vaccine in mice immunized intradermally.</ArticleTitle><Pagination><StartPage>2209472</StartPage><MedlinePgn>2209472</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">2209472</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1080/21645515.2023.2209472</ELocationID><Abstract><AbstractText>Hand, foot and mouth disease is a common acute viral infectious disease that poses a serious threat to the life and health of young children. With the development of an effective inactivated EV71 vaccine, CA16 has become the main pathogen causing HFMD. Effective and safe vaccines against this disease are urgently needed. In our previous study, a bivalent inactivated vaccine was shown to have good immunogenicity and to induce neutralizing antibodies in mice and monkeys. Repeated administration toxicity is a critical safety test in the preclinical evaluation of vaccines. In this study, BALB/c mice were used to evaluate the toxicity of the bivalent vaccine after multiple intradermal administrations. Clinical observation was performed daily, and body weight, food intake, hematological characteristics, serum biochemical parameters, antinuclear antibodies, CD4<sup>+</sup>/CD8a<sup>+</sup> T-cell proportions, bone marrow smear results and pathology results were recorded. The results showed that there was no significant change at the injection site and no adverse reactions related to the vaccine. The bivalent inactivated EV71-CA16 vaccine exhibits good safety in mice, and these results provide a sufficient basis for further clinical trials.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Liao</LastName><ForeName>Yun</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Institute of Medical Biology, Chinese Academy of Medical Sciences &amp; Peking Union Medical College, Yunnan Key Laboratory of Vaccine Research and Development on Severe Infectious Diseases, Kunming, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Qinfang</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Institute of Medical Biology, Chinese Academy of Medical Sciences &amp; Peking Union Medical College, Yunnan Key Laboratory of Vaccine Research and Development on Severe Infectious Diseases, Kunming, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huo</LastName><ForeName>Xinqian</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Institute of Medical Biology, Chinese Academy of Medical Sciences &amp; Peking Union Medical College, Yunnan Key Laboratory of Vaccine Research and Development on Severe Infectious Diseases, Kunming, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Li</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Institute of Medical Biology, Chinese Academy of Medical Sciences &amp; Peking Union Medical College, Yunnan Key Laboratory of Vaccine Research and Development on Severe Infectious Diseases, Kunming, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Jinling</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Institute of Medical Biology, Chinese Academy of Medical Sciences &amp; Peking Union Medical College, Yunnan Key Laboratory of Vaccine Research and Development on Severe Infectious Diseases, Kunming, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Heng</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Institute of Medical Biology, Chinese Academy of Medical Sciences &amp; Peking Union Medical College, Yunnan Key Laboratory of Vaccine Research and Development on Severe Infectious Diseases, Kunming, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Dandan</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Institute of Medical Biology, Chinese Academy of Medical Sciences &amp; Peking Union Medical College, Yunnan Key Laboratory of Vaccine Research and Development on Severe Infectious Diseases, Kunming, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Xingli</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Institute of Medical Biology, Chinese Academy of Medical Sciences &amp; Peking Union Medical College, Yunnan Key Laboratory of Vaccine Research and Development on Severe Infectious Diseases, Kunming, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Guorun</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Institute of Medical Biology, Chinese Academy of Medical Sciences &amp; Peking Union Medical College, Yunnan Key Laboratory of Vaccine Research and Development on Severe Infectious Diseases, Kunming, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Caixing</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Institute of Medical Biology, Chinese Academy of Medical Sciences &amp; Peking Union Medical College, Yunnan Key Laboratory of Vaccine Research and Development on Severe Infectious Diseases, Kunming, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Cong</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Institute of Medical Biology, Chinese Academy of Medical Sciences &amp; Peking Union Medical College, Yunnan Key Laboratory of Vaccine Research and Development on Severe Infectious Diseases, Kunming, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Yun</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Institute of Medical Biology, Chinese Academy of Medical Sciences &amp; Peking Union Medical College, Yunnan Key Laboratory of Vaccine Research and Development on Severe Infectious Diseases, Kunming, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Ying</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Institute of Medical Biology, Chinese Academy of Medical Sciences &amp; Peking Union Medical College, Yunnan Key Laboratory of Vaccine Research and Development on Severe Infectious Diseases, Kunming, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shao</LastName><ForeName>Mingxiang</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Shandong Xinbo Pharmaceutical R&amp;D Co. Ltd, Dezhou, Shandong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Baofeng</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Shandong Xinbo Pharmaceutical R&amp;D Co. Ltd, Dezhou, Shandong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shen</LastName><ForeName>Lianzhong</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Shandong Xinbo Pharmaceutical R&amp;D Co. Ltd, Dezhou, Shandong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fan</LastName><ForeName>Shengtao</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-4412-8391</Identifier><AffiliationInfo><Affiliation>Institute of Medical Biology, Chinese Academy of Medical Sciences &amp; Peking Union Medical College, Yunnan Key Laboratory of Vaccine Research and Development on Severe Infectious Diseases, Kunming, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Qihan</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Institute of Medical Biology, Chinese Academy of Medical Sciences &amp; Peking Union Medical College, Yunnan Key Laboratory of Vaccine Research and Development on Severe Infectious Diseases, Kunming, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Hum Vaccin Immunother</MedlineTA><NlmUniqueID>101572652</NlmUniqueID><ISSNLinking>2164-5515</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015164">Vaccines, Inactivated</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006232" MajorTopicYN="Y">Hand, Foot and Mouth Disease</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="Y">Enterovirus A, Human</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015164" MajorTopicYN="N">Vaccines, Inactivated</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014765" MajorTopicYN="Y">Viral Vaccines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">EV71-CA16 inactivated vaccine</Keyword><Keyword MajorTopicYN="N">preclinical evaluation</Keyword><Keyword MajorTopicYN="N">safety</Keyword><Keyword MajorTopicYN="N">toxicity</Keyword></KeywordList><CoiStatement>No potential conflict of interest was reported by the author(s).</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>24</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>5</Month><Day>23</Day><Hour>1</Hour><Minute>6</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>5</Month><Day>22</Day><Hour>19</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>5</Month><Day>22</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37217189</ArticleId><ArticleId IdType="pmc">PMC10208166</ArticleId><ArticleId IdType="doi">10.1080/21645515.2023.2209472</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Esposito S, Principi N.. Hand, foot and mouth disease: current knowledge on clinical manifestations, epidemiology, aetiology and prevention. Eur J Clin Microbiol Infect Dis. 2018;37(3):391–12. doi:10.1007/s10096-018-3206-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10096-018-3206-x</ArticleId><ArticleId IdType="pubmed">29411190</ArticleId></ArticleIdList></Reference><Reference><Citation>Li D, Su M, Sun P-P, Guo W-P, Wang C-Y, Wang J-L, Wang H, Zhang Q, Du L-Y, Xie G-C.. Global profiling of the alternative splicing landscape reveals transcriptomic diversity during the early phase of enterovirus 71 infection. Virology. 2020;548:213–25. doi:10.1016/j.virol.2020.06.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2020.06.011</ArticleId><ArticleId IdType="pubmed">32763492</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu SL, Pan H, Liu P, Amer S, Chan T-C, Zhan J, Huo X, Liu Y, Teng Z, Wang L, et al. Comparative epidemiology and virology of fatal and nonfatal cases of hand, foot and mouth disease in mainland China from 2008 to 2014. Rev Med Virol. 2015;25(2):115–28. doi:10.1002/rmv.1827.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/rmv.1827</ArticleId><ArticleId IdType="pubmed">25704797</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu S, Liao Q, Zhou Y, Hu S, Chen Q, Luo K, Chen Z, Luo L, Huang W, Dai B, et al. Population based hospitalization burden of laboratory-confirmed hand, foot and mouth disease caused by multiple enterovirus serotypes in Southern China. PLoS One. 2018;13(12):e0203792. doi:10.1371/journal.pone.0203792.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0203792</ArticleId><ArticleId IdType="pmc">PMC6292616</ArticleId><ArticleId IdType="pubmed">30543631</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan S, Liao Y, Jiang G, Wang L, Zhao H, Yu L, Xu X, Li D, Zhang Y, Li Q. Efficacy of an inactivated bivalent vaccine for enterovirus 71 and coxsackievirus A16 in mice immunized intradermally. Vaccine. 2021;39(3):596–604. doi:10.1016/j.vaccine.2020.11.070.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2020.11.070</ArticleId><ArticleId IdType="pubmed">33342637</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan S, Liao Y, Jiang G, Jiang L, Wang L, Xu X, Feng M, Yang E, Zhang Y, Cui W, et al. Study of integrated protective immunity induced in rhesus macaques by the intradermal administration of a bivalent EV71-CA16 inactivated vaccine. Vaccine. 2020;38(8):2034–44. doi:10.1016/j.vaccine.2019.12.057.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2019.12.057</ArticleId><ArticleId IdType="pubmed">31982260</ArticleId></ArticleIdList></Reference><Reference><Citation>Forster R. Study designs for the nonclinical safety testing of new vaccine products. J Pharmacol Toxicol Methods. 2012;66(1):1–7. doi:10.1016/j.vascn.2012.04.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vascn.2012.04.003</ArticleId><ArticleId IdType="pubmed">22561062</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun Y, Gruber M, Matsumoto M. Overview of global regulatory toxicology requirements for vaccines and adjuvants. J Pharmacol Toxicol Methods. 2012;65(2):49–57. doi:10.1016/j.vascn.2012.01.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vascn.2012.01.002</ArticleId><ArticleId IdType="pubmed">22326278</ArticleId></ArticleIdList></Reference><Reference><Citation>Barrow P. Developmental and reproductive toxicity testing of vaccines. J Pharmacol Toxicol Methods. 2012;65(2):58–63. doi:10.1016/j.vascn.2011.12.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vascn.2011.12.001</ArticleId><ArticleId IdType="pubmed">22233769</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu L, Zhang Y, Wang J, Zhao H, Jiang L, Che Y, Shi H, Li R, Mo Z, Huang T, et al. Study of the integrated immune response induced by an inactivated EV71 vaccine. PLoS One. 2013;8(1):e54451. doi:10.1371/journal.pone.0054451.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0054451</ArticleId><ArticleId IdType="pmc">PMC3553120</ArticleId><ArticleId IdType="pubmed">23372725</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan S, Liao Y, Lian Y, Jiang G, Jiang L, Dong C, Yang E, Wang L, Xu X, Feng M, et al. Role of innate lymphoid cells and dendritic cells in intradermal immunization of the enterovirus antigen. NPJ Vaccines. 2019;4(1):14. doi:10.1038/s41541-019-0108-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41541-019-0108-6</ArticleId><ArticleId IdType="pmc">PMC6437170</ArticleId><ArticleId IdType="pubmed">30937186</ArticleId></ArticleIdList></Reference><Reference><Citation>Pizzi M. Sampling variation of the fifty percent end-point, determined by the Reed-Muench (Behrens) method. Hum Biol. 1950;22:151–90.</Citation><ArticleIdList><ArticleId IdType="pubmed">14778593</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang J, Liao Q, Ooi MH, Cowling BJ, Chang Z, Wu P, Liu F, Li Y, Luo L, Yu S, et al. Epidemiology of recurrent hand, foot and mouth disease, China, 2008–2015. Emerg Infect Dis. 2018;24(3)432. doi:10.3201/eid2403.171303.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid2403.171303</ArticleId><ArticleId IdType="pmc">PMC5823341</ArticleId><ArticleId IdType="pubmed">29460747</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhuang ZC, Kou Z-Q, Bai Y-J, Cong X, Wang L-H, Li C, Zhao L, Yu X-J, Wang Z-Y, Wen H-L. Epidemiological research on hand, foot, and mouth disease in Mainland China. Viruses. 2015;7(12):6400–11. doi:10.3390/v7122947.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v7122947</ArticleId><ArticleId IdType="pmc">PMC4690870</ArticleId><ArticleId IdType="pubmed">26690202</ArticleId></ArticleIdList></Reference><Reference><Citation>Li R, Liu L, Mo Z, Wang X, Xia J, Liang Z, Zhang Y, Li Y, Mao Q, Wang J, et al. An inactivated enterovirus 71 vaccine in healthy children. N Engl J Med. 2014;370(9):829–37. doi:10.1056/NEJMoa1303224.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1303224</ArticleId><ArticleId IdType="pubmed">24571755</ArticleId></ArticleIdList></Reference><Reference><Citation>Saguil A, Kane SF, Lauters R, Mercado MG. Hand-foot-and-mouth disease: rapid evidence review. Am Fam Physician. 2019;100:408–14.</Citation><ArticleIdList><ArticleId IdType="pubmed">31573162</ArticleId></ArticleIdList></Reference><Reference><Citation>Jia J, Kong F, Xin X, Liang J, Xin H, Dong L, Jiang F. Epidemiological characteristics of hand, foot, and mouth disease outbreaks in Qingdao, 2009-2018. Iran J Public Health. 2021;50(5):999–1008. doi:10.18502/ijph.v50i5.6117.</Citation><ArticleIdList><ArticleId IdType="doi">10.18502/ijph.v50i5.6117</ArticleId><ArticleId IdType="pmc">PMC8223573</ArticleId><ArticleId IdType="pubmed">34183958</ArticleId></ArticleIdList></Reference><Reference><Citation>He X, Zhang M, Zhao C, Zheng P, Zhang X, Xu J. From monovalent to multivalent vaccines, the exploration for potential preventive strategies against hand, foot, and mouth disease (HFMD). Virol Sin. 2021;36(2):167–75. doi:10.1007/s12250-020-00294-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12250-020-00294-3</ArticleId><ArticleId IdType="pmc">PMC7525078</ArticleId><ArticleId IdType="pubmed">32997323</ArticleId></ArticleIdList></Reference><Reference><Citation>CDE, 2008 (China) . The general principles for the technical review of pre-clinical safety evaluation of biological products for prevention.</Citation></Reference><Reference><Citation>Verdier F, Barrow PC, Burge J. Reproductive toxicity testing of vaccines. Toxicology. 2003;185(3):213–9. doi:10.1016/S0300-483X(02)00611-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0300-483X(02)00611-X</ArticleId><ArticleId IdType="pubmed">12581696</ArticleId></ArticleIdList></Reference><Reference><Citation>Lebron JA, Wolf JJ, Kaplanski CV, Ledwith BJ. Ensuring the quality, potency and safety of vaccines during preclinical development. Expert Rev Vaccines. 2005;4(6):855–66. doi:10.1586/14760584.4.6.855.</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/14760584.4.6.855</ArticleId><ArticleId IdType="pubmed">16372881</ArticleId></ArticleIdList></Reference><Reference><Citation>Baldrick P. Dose site reactions and related findings after vaccine administration in safety studies. J Appl Toxicol. 2016;36(8):980–90. doi:10.1002/jat.3314.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jat.3314</ArticleId><ArticleId IdType="pubmed">26968331</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Z, Zhou C, Gao F, Zhu Q, Jiang Y, Ma X, Hu Y, Shi L, Wang X, Zhang C, et al. Preclinical evaluation of recombinant HFMD vaccine based on enterovirus 71 (EV71) virus-like particles (VLP): immunogenicity, efficacy and toxicology. Vaccine. 2021;39(31):4296–305. doi:10.1016/j.vaccine.2021.06.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2021.06.031</ArticleId><ArticleId IdType="pubmed">34167837</ArticleId></ArticleIdList></Reference><Reference><Citation>Salari S, Sharifi I, Keyhani AR, Ghasemi Nejad Almani P. Evaluation of a new live recombinant vaccine against cutaneous leishmaniasis in BALB/c mice. Parasit Vectors. 2020;13(1):415. doi:10.1186/s13071-020-04289-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13071-020-04289-7</ArticleId><ArticleId IdType="pmc">PMC7425157</ArticleId><ArticleId IdType="pubmed">32787908</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakayama T. An inflammatory response is essential for the development of adaptive immunity-immunogenicity and immunotoxicity. Vaccine. 2016;34(47):5815–8. doi:10.1016/j.vaccine.2016.08.051.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2016.08.051</ArticleId><ArticleId IdType="pubmed">27745952</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Z, Jiang Q, Wang Y, Yang J, Du T, Yi H, Li C, Li Y, Wu Z, Fan S, et al. SARS-CoV-2 inactivated vaccine (Vero cells) shows good safety in repeated administration toxicity test of Sprague Dawley rats. Food Chem Toxicol. 2021;152:112239. doi:10.1016/j.fct.2021.112239.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.fct.2021.112239</ArticleId><ArticleId IdType="pmc">PMC8064818</ArticleId><ArticleId IdType="pubmed">33901607</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>